Hospital

The panelists reviewed current treatments for Clostridioides difficile infection and how they can be applied to special patient populations, as well as what treatments can be expected in the future.

Rivaroxaban and apixaban are the most commonly prescribed direct oral anticoagulants, although they may be most effective in different populations.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

Amid the current shortage in the pharmacy technician workforce, career ladder programs could improve pharmacy technician recruitment and retention rates.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

Results highlight sustained benefits of avapritinib in patients with advanced systemic mastocytosis.

Ten quiz questions to assess your knowledge on common symptoms and treatments for endometrial cancer.

Families and providers can use a flexible infusion schedule to meet patient needs, Octapharma says.

Fibromuscular dysplasia typically appears in the arteries leading to the kidneys and brain.

Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Tamoxifen is given to many patients—specifically premenopausal patients—with breast cancers that express the estrogen receptor, which drives breast tumor growth.

Patients ages 80 and older have unique considerations when deciding whether to initiate anticoagulation therapy.

Moderna COVID-19 vaccine found to offer an increased level of protection, including a 21% reduced risk of documented infection and 41% lower risk of hospitalization.

In part 2 of the discussion, Lodise said the decision of which drugs to use for various infections is very nuanced, but the new guidance document utilized the best available evidence.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.

Pyrotinib combined with capecitabine found to improve overall survival in patients with previously treated HER2-positive metastatic breast cancer.

Phase 3 induction study results show that the drug achieved a positive endoscopic response at week 12

Rylaze is a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.

Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

In the case reviewed, the pharmacy department created an interdisciplinary Biosimilar Task Force responsible for making decisions relating to the adoption of biosimilar therapies.

The findings of a study showed redistribution and standardization of prior authorization processes within health systems allowed pharmacy technicians reduce the burden on staff members from other roles.

Study subject was based around the 4 pillars of clinical academia: practice, scholarship, service, and teaching.

In the study, the investigators observed that by elevating technicians to advanced analytics roles, pharmacies could develop user-friendly data collection tools and data analytics.

The case study details the methodology employed by a large academic medical center to convert its medication history technician program’s workflow from on-site with in-person patient interviews to completely remote services.

Nakia Eldridge, PharmD, MPH, senior manager of health care quality, safety, and information at US Pharmacopeia (USP), and Lindsey Clawson, MBA, USP’s lead of COVID-19 vaccine strategy, discuss the latest updates in USP’s COVID-19 Vaccine Handling Toolkit.

FDA to evaluate luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent β-thalassemia.